Yuhan Corporation Hits Another 'Home Run'... 500 Billion KRW Scale New Drug Technology Export

Lee Jeong-hee, CEO of Yuhan Corporation

[Asia Economy Reporter Cho Hyun-ui] Yuhan Corporation announced on the 20th that it has signed a technology licensing agreement worth 500 billion KRW for the functional gastrointestinal disease treatment new drug (YH12852) with the U.S. pharmaceutical company Processa Pharmaceuticals.

Under this agreement, Processa Pharmaceuticals will have exclusive rights to develop, manufacture, and commercialize YH12852 in the global market. Yuhan Corporation retains the rights for development and commercialization within South Korea.

Yuhan Corporation will receive a non-refundable signing fee of 2 million USD (approximately 2.4 billion KRW) and will also receive milestone payments as clinical trials progress. Additionally, royalties will be paid as a certain percentage of sales once the product is marketed. The total amount Yuhan Corporation can receive if YH12852 successfully completes clinical trials, approval, and commercialization is up to 410.5 million USD (approximately 500 billion KRW).

YH12852 is a synthetic new drug developed independently by Yuhan Corporation, acting as an agonist with excellent selectivity for the 5-HT4 receptor. Although the existing approved drug cisapride showed therapeutic effects in various gastrointestinal motility disorders, it was withdrawn or had restricted indications due to serious cardiovascular side effects caused by its low selectivity for the 5-HT4 receptor.

A Yuhan Corporation official stated, "YH12852 has already undergone preclinical toxicity studies and Phase 1 clinical trials in Korea," adding, "Since it demonstrated excellent gastrointestinal motility improvement effects without cardiovascular side effects, rapid follow-up clinical development in the U.S. is expected to be possible."

This content was produced with the assistance of AI translation services.